Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Novel potential Gaucher's disease drugs designed in U.S.

July 11, 2012

ISU Abxis reports on phase II program for Fabry's disease

July 11, 2012

Repros reaches agreement with FDA on pivotal Androxal studies

July 10, 2012

Novel DPP IV inhibitors prepared

July 10, 2012

Lupin presents novel GLP-1 receptor modulators

July 10, 2012

New long-acting drug is well tolerated as once-weekly growth hormone replacement therapy

July 10, 2012

Pfizer grants ChemRar rights to DPP IV inhibitor

July 6, 2012

New LDL-PLA2 inhibitors developed by GlaxoSmithKline

July 6, 2012

U.S. university presents novel inhibitors of PRCP

July 5, 2012

Novel compounds for bone disorders designed in Japan

July 5, 2012

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...